AR083579A1 - Inhibidor de cetp de oxazodilinona sustituida con amina ciclica - Google Patents
Inhibidor de cetp de oxazodilinona sustituida con amina ciclicaInfo
- Publication number
- AR083579A1 AR083579A1 ARP110103977A ARP110103977A AR083579A1 AR 083579 A1 AR083579 A1 AR 083579A1 AR P110103977 A ARP110103977 A AR P110103977A AR P110103977 A ARP110103977 A AR P110103977A AR 083579 A1 AR083579 A1 AR 083579A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- independently
- halogens
- halogen
- Prior art date
Links
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title abstract 2
- -1 CYCLINE AMINE Chemical group 0.000 title 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 24
- 150000002367 halogens Chemical class 0.000 abstract 24
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 15
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000003950 cyclic amides Chemical group 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40830810P | 2010-10-29 | 2010-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083579A1 true AR083579A1 (es) | 2013-03-06 |
Family
ID=45994352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103977A AR083579A1 (es) | 2010-10-29 | 2011-10-27 | Inhibidor de cetp de oxazodilinona sustituida con amina ciclica |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9221834B2 (enExample) |
| EP (1) | EP2632269B1 (enExample) |
| JP (1) | JP5852662B2 (enExample) |
| CN (1) | CN103269592B (enExample) |
| AR (1) | AR083579A1 (enExample) |
| AU (1) | AU2011320665B2 (enExample) |
| CA (1) | CA2814846A1 (enExample) |
| ES (1) | ES2623759T3 (enExample) |
| TW (1) | TW201305146A (enExample) |
| WO (1) | WO2012058187A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| WO2013165854A1 (en) * | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Cyclic amine substituted heterocyclic cetp inhibitors |
| CN103958484B (zh) * | 2012-07-19 | 2015-11-25 | 上海恒瑞医药有限公司 | 噁唑烷酮类衍生物、其制备方法及其在医药上的应用 |
| CN102977044A (zh) * | 2012-11-26 | 2013-03-20 | 盛世泰科生物医药技术(苏州)有限公司 | 一种3-(4-甲氧基苯基)-异噁唑-5-羧酸的制备方法 |
| EP2934518B1 (en) | 2012-12-19 | 2020-02-19 | Merck Sharp & Dohme Corp. | Spirocyclic cetp inhibitors |
| WO2014099834A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Therapeutic thiazolidinone compounds |
| AU2014213125B2 (en) * | 2013-01-31 | 2016-06-02 | Chong Kun Dang Pharmaceutical Corp. | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors |
| EP3027619B1 (en) | 2013-07-30 | 2019-01-02 | Merck Sharp & Dohme Corp. | Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors |
| US9688630B2 (en) | 2013-10-10 | 2017-06-27 | Merck Sharp & Dohme Corp. | 3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein |
| US9663534B2 (en) | 2013-12-17 | 2017-05-30 | Merck Sharp & Dohme Corp. | Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| EP3174537B1 (en) * | 2014-07-29 | 2021-06-23 | Merck Sharp & Dohme Corp. | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| EP3191445B1 (en) * | 2014-09-09 | 2019-06-12 | Bristol-Myers Squibb Company | Cyclobutane containing carboxylic acid gpr120 modulators |
| WO2017011279A1 (en) | 2015-07-13 | 2017-01-19 | Merck Sharp & Dohme Corp. | Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein |
| KR20200091395A (ko) * | 2017-09-27 | 2020-07-30 | 페도라 파마슈티칼스 인코포레이티드 | 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| HN2005000340A (es) * | 2004-07-02 | 2009-11-06 | Merck Sharp & Dohme | Inhibidores de cetp |
| DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| WO2007081569A2 (en) * | 2005-12-30 | 2007-07-19 | Merck & Co., Inc. | Cetp inhibitors |
| JP5040036B2 (ja) | 2005-12-30 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｅｔｐ阻害剤として有用な１，３−オキサゾリジン−２−オン誘導体 |
| US7781426B2 (en) | 2005-12-30 | 2010-08-24 | Merck Sharp & Dohme Corp. | CETP inhibitors |
| WO2011028395A1 (en) * | 2009-08-24 | 2011-03-10 | Merck Sharp & Dohme Corp. | Pyridyl oxazolidinone cetp inhibitor |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| WO2013165854A1 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Cyclic amine substituted heterocyclic cetp inhibitors |
-
2011
- 2011-10-25 CA CA2814846A patent/CA2814846A1/en not_active Abandoned
- 2011-10-25 CN CN201180062829.9A patent/CN103269592B/zh not_active Expired - Fee Related
- 2011-10-25 AU AU2011320665A patent/AU2011320665B2/en not_active Ceased
- 2011-10-25 ES ES11836937.0T patent/ES2623759T3/es active Active
- 2011-10-25 JP JP2013536709A patent/JP5852662B2/ja not_active Expired - Fee Related
- 2011-10-25 EP EP11836937.0A patent/EP2632269B1/en active Active
- 2011-10-25 US US13/881,896 patent/US9221834B2/en active Active
- 2011-10-25 WO PCT/US2011/057584 patent/WO2012058187A1/en not_active Ceased
- 2011-10-27 AR ARP110103977A patent/AR083579A1/es not_active Application Discontinuation
- 2011-10-28 TW TW100139480A patent/TW201305146A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2623759T3 (es) | 2017-07-12 |
| JP5852662B2 (ja) | 2016-02-03 |
| AU2011320665A1 (en) | 2013-05-09 |
| AU2011320665B2 (en) | 2015-09-03 |
| EP2632269B1 (en) | 2017-03-15 |
| JP2013544805A (ja) | 2013-12-19 |
| TW201305146A (zh) | 2013-02-01 |
| US9221834B2 (en) | 2015-12-29 |
| EP2632269A4 (en) | 2015-01-21 |
| EP2632269A1 (en) | 2013-09-04 |
| US20130331372A1 (en) | 2013-12-12 |
| CN103269592A (zh) | 2013-08-28 |
| CA2814846A1 (en) | 2012-05-03 |
| CN103269592B (zh) | 2016-05-11 |
| WO2012058187A1 (en) | 2012-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591429A1 (ru) | 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена | |
| AR087311A1 (es) | Quinolinas sustituidas y su uso como medicamentos | |
| AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
| ECSP14002458A (es) | Inhibidor de cetp de oxazolidona biciclico fusionado | |
| CR20160296A (es) | Benzamidas sustituidas y métodos para usarlas | |
| CL2016000916A1 (es) | Co-cristales que comprenden un compuesto derivado de quinolina-2carboxamida de fórmula (i) y un formador de cristales; composiciones que los comprenden; método de preparación de los co-cristales y uso de estos en la preparación de un medicamento útil para el tratamiento de cáncer | |
| NI201500130A (es) | 2-azabiciclo sustituidos y su uso como moduladores del receptor de orexina | |
| PE20210922A1 (es) | Pirimidinonas como inhibidores del factor xia | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| PE20151860A1 (es) | Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd | |
| AR093759A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| MX338078B (es) | Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos. | |
| CL2018000241A1 (es) | Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il) propanoico sustituido. | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| EA201591360A1 (ru) | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств | |
| EA201690844A1 (ru) | Ингибиторы gsk-3 | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| HUE053112T2 (hu) | PDE 4 inhibitor kristályos formája | |
| NZ701894A (en) | Dimethyl-benzoic acid compounds | |
| EA201691162A1 (ru) | Способы получения соединений бензохинолина | |
| MX380619B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| CL2015002712A1 (es) | Cristales de laquinimod sódico y proceso para la preparación de ellos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |